Insider Buying: NextCure (NASDAQ:NXTC) Major Shareholder Buys $31,680.00 in Stock

NextCure, Inc. (NASDAQ:NXTC) major shareholder Adar1 Capital Management, Llc bought 6,400 shares of the stock in a transaction on Tuesday, July 28th. The shares were bought at an average price of $4.95 per share, for a total transaction of $31,680.00. Following the purchase, the insider directly owned 389,856 shares in the company, valued at approximately $1,929,787.20. This trade represents a 1.67% increase in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Major shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Adar1 Capital Management, Llc also recently made the following trade(s):

• On Wednesday, July 29th, Adar1 Capital Management, Llc purchased 3,410 shares of NextCure stock. The stock was bought at an average price of $5.00 per share, with a total value of $17,050.00.
• On Monday, July 27th, Adar1 Capital Management, Llc purchased 7,798 shares of NextCure stock. The stock was bought at an average price of $5.00 per share, with a total value of $38,990.00.

NextCure Stock Down 17.7%

NXTC opened at $4.14 on Friday. The firm has a 50 day moving average price of $3.49 and a 200-day moving average price of $8.68. NextCure, Inc. has a twelve month low of $1.55 and a twelve month high of $15.74. The stock has a market capitalization of $14.95 million, a price-to-earnings ratio of -0.24 and a beta of 1.42.

NextCure (NASDAQ:NXTC) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($1.87) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.10) by $0.23. As a group, analysts expect that NextCure, Inc. will post -7.89 earnings per share for the current year.

Institutional Trading of NextCure

Several large investors have recently added to or reduced their stakes in NXTC. Marshall Wace LLP purchased a new stake in NextCure during the fourth quarter valued at approximately $160,000. Millennium Management LLC bought a new position in NextCure in the fourth quarter worth approximately $185,000. Geode Capital Management LLC boosted its stake in shares of NextCure by 18.6% during the 4th quarter. Geode Capital Management LLC now owns 23,157 shares of the company’s stock worth $329,000 after acquiring an additional 3,636 shares during the last quarter. Cable Car Capital LP boosted its stake in shares of NextCure by 13.1% during the 2nd quarter. Cable Car Capital LP now owns 758,141 shares of the company’s stock worth $349,000 after acquiring an additional 88,040 shares during the last quarter. Finally, Renaissance Technologies LLC grew its position in shares of NextCure by 18.7% during the 4th quarter. Renaissance Technologies LLC now owns 33,634 shares of the company’s stock valued at $477,000 after acquiring an additional 5,300 shares during the period. 42.65% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on NXTC shares. Weiss Ratings cut NextCure from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, July 7th. Zacks Research raised NextCure from a “strong sell” rating to a “hold” rating in a report on Thursday, June 11th. Wall Street Zen cut NextCure from a “hold” rating to a “sell” rating in a research report on Saturday, July 18th. Finally, HC Wainwright reissued a “buy” rating and issued a $20.00 target price on shares of NextCure in a report on Wednesday, July 15th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, NextCure presently has a consensus rating of “Hold” and an average target price of $19.00.

About NextCure

NextCure, Inc is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel immune modulators for the treatment of cancer and inflammatory diseases. Leveraging its proprietary Therapeutic Discovery Engine (TDE™), the company aims to identify, validate and optimize new targets in the immune response pathway. NextCure’s research platform integrates large‐scale proteomics and functional genomics to accelerate the progression of promising therapeutic candidates from early discovery through clinical development.

The company’s pipeline includes multiple product candidates in various stages of preclinical and clinical evaluation.